Affiliation:
1. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
2. Department of Pulmonology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
3. Department of Pharmacy and Pharmacology, Erasmus University Medical Center, Rotterdam, the Netherlands
Abstract
Background: Alectinib is the keystone treatment in advanced anaplastic lymphoma kinase–positive (ALK+) non–small cell lung cancer (NSCLC). An exposure–response threshold of 435 ng/mL has recently been established, albeit 37% of patients do not reach this threshold. Alectinib is orally administered, and absorption is largely influenced by food. Hence, further investigation into this relationship is needed to optimize its bioavailability. Patients and Methods: In this randomized 3-period crossover clinical study in ALK+ NSCLC, alectinib exposure was compared among patients with different diets. Every 7 days, the first alectinib dose was taken with either a continental breakfast, 250-g of low-fat yogurt, or a self-chosen lunch, and the second dose was taken with a self-chosen dinner. Sampling for alectinib exposure (Ctrough) was performed at day 8, just prior to alectinib intake, and the relative difference in Ctrough was compared. Results: In 20 evaluable patients, the mean Ctrough was 14% (95% CI, −23% to −5%; P=.009) and 20% (95% CI, −25% to −14%; P<.001) lower when taken with low-fat yogurt compared with a continental breakfast and a self-chosen lunch, respectively. Administration with a self-chosen lunch did not change exposure compared with a continental breakfast (+7%; 95% CI, −2% to +17%; P=.243). In the low-fat yogurt period, 35% of patients did not reach the threshold versus 5% with the other meals (P<.01). Conclusions: Patients and physicians should be warned for a detrimental food–drug interaction when alectinib is taken with low-fat yogurt, because it results in a clinically relevant lower alectinib exposure. Intake with a self-chosen lunch did not change drug exposure and could be a safe and patient-friendly alternative.
Reference31 articles.
1. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study;Camidge DR,2019
2. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria JC,2018
3. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial;Planchard D,2017
4. Product information
5. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors;Chia PL,2014
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献